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Background: Periprosthetic joint infection (PJI) is the third leading cause of total
hip arthroplasty (THA) failure. Although controversial, 2-stage revision remains the
gold standard treatment for PJI in most situations. To date, there have been few
studies describing the economic impact of PJI in today’s health care environment.
The purpose of the current study was to obtain an accurate estimate of the institutional cost associated with the management of PJI in THA and to assess the economic burden of PJI compared with primary uncomplicated THA.
Methods: We conducted a review of primary THA cases and 2-stage revision THA
for PJI at our institution. Patients were matched for age and body mass index. All
costs associated with each procedure were recorded. Descriptive statistics were used to
summarize the collected data. Mean costs, length of stay, clinic visits and readmission
rates associated with the 2 cohorts were compared.
Results: Fifty consecutive cases of revision THA were matched with 50 cases of
uncomplicated primary THA between 2006 and 2014. Compared with the primary
THA cohort, PJI was associated with a significant increase in mean length of hospital stay (26.5 v. 2.0 d, p < 0.001), mean number of clinic visits (9.2 v. 3.8,
p < 0.001), number of readmissions (12 v. 1, p < 0.001) and average overall cost
(Can$38 107 v. Can$6764, t = 8.3, p < 0.001).
Conclusion: Treatment of PJI is a tremendous economic burden. Our data suggest
a 5-fold increase in hospital expenditure in the management of PJI compared with
primary uncomplicated THA.
Contexte : L’infection articulaire périprothétique (IAP) arrive au troisième rang
des principales causes d’échec de l’arthroplastie (ou prothèse) totale de la hanche
(PTH). Même si elle est controversée, la révision en 2 étapes demeure le traitement
standard pour l’IAP dans la plupart des cas. À ce jour, peu d’études ont décrit
l’impact économique de l’IAP dans l’environnement actuel des soins de santé. Le
but de la présente étude était d’obtenir une estimation précise des coûts institutionnels associés à la prise en charge de l’IAP dans la PTH et d’évaluer le fardeau
économique de l’IAP comparativement à une PTH primaire non compliquée.
Méthodes : Nous avons passé en revue les cas de PTH primaire et de révision
de PTH en 2 étapes pour cause d’IAP dans notre établissement. Les patients
ont été assortis selon l’âge et l’indice de masse corporelle. Tous les coûts associés
à chaque intervention ont été consignés. Des statistiques descriptives ont servi
à résumer les données recueillies. Nous avons comparé les coûts moyens, la
durée des séjours, les visites à la clinique et les taux de réadmission associés aux
2 cohortes.
Résultats : Cinquante cas consécutifs de révision de PTH ont été assortis à
50 cas de PTH primaire non compliquée entre 2006 et 2014. Comparativement
à la cohorte de PTH primaire, les cas d’IAP ont été associés à une augmentation
significative de la durée moyenne du séjour hospitalier (26,5 j c. 2,0 j, p < 0,001),
du nombre moyen de visites à la clinique (9,2 c. 3,8, p < 0,001), du nombre
des réadmissions (12 c. 1, p < 0,001) et du coût global moyen (38 107 $ CA
c. 6764 $ CA, t = 8,3, p < 0,001).
Conclusion : Le traitement de l’IAP représente un énorme fardeau économique.
Selon nos données, les dépenses hospitalières associées à sa prise en charge sont 5 fois
plus grandes que pour la PTH primaire non compliquée.
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eep infection is a devastating complication in total
hip arthroplasty (THA) resulting in significant
patient and institutional burden. Current literature suggests that the incidence of periprosthetic joint
infection (PJI) is 1%–2%, and it is projected to increase
as the population ages and as indications for THA continue to expand.1–6 In North America, 2-stage revision
surgery remains the gold standard in treatment, leading
to successful eradication of infection in up 90% of
patients with PJI.7,8 Most of these revisions are performed
in tertiary care centres by surgeons with specialty training
in adult reconstructive surgery.9 By its nature, treatment
is a costly institutional endeavour, requiring multiple surgeries and hospital admissions. Previous studies suggest a
2- to 4-fold increase in health care expenditure for PJI
compared with primary uncomplicated THA. 6,10,11,12
These expenditures are largely driven by length of hospital stay, operating room expenses, implants and inpatient
resource use. To date, much of our knowledge in this
area has been obtained from large-volume databases,
where costs have often been derived from hospital billings rather than from direct institutional case costing
data.6,7,11 This makes it difficult to extrapolate findings to
other facilities and health care models and, in turn, may
limit our ability to identify potential for cost containment
at the institutional level. Cost data have become particularly important with the emergence of quality-based
funding or bundled reimbursement models, which
require surgeons to be cost conscious while providing
high-quality, equitable care. With this in mind, the purpose of our study was to obtain an accurate estimate of
the institutional cost associated with the management of
PJI in THA and to assess the economic burden of PJI
compared with primary THA with respect to direct institutional cost and hospital resource utilization.

Methods
This was a single-centre, retrospective study that compared patients who underwent 2-stage revision for infection with a cohort of patients matched on age and body
mass index (BMI) who underwent uncomplicated primary
THA between 2006 and 2014. The diagnosis of PJI was
made using the Musculoskeletal Infection Society’s cri
teria.13 Osteoarthritis was the indication for all primary
THA. Patients with prior ipsilateral revision hip surgery
and patients who died before second-stage revision were
excluded. All patients had a minimum follow-up of 2 years.
All cost- and procedure-related data were obtained from
an institutional database at a single Canadian academic
centre. Information in this database reflects the practices of
6 fellowship-trained arthroplasty surgeons.
We identified 61 consecutive cases of infected THA
between 2012 and 2014. Fifty patients met the inclusion
criteria and were thus entered into our analysis. A compar-

ative cohort of 50 consecutive cases of primary THA was
matched to the cohort of patients with infected THA on
the basis of age and body mass index (BMI) and was used
to establish a control group. Data pertaining to inpatient
resource utilization were collected by a single independent
reviewer, using an electronic medical record system. Unit
costs pertaining to operating time, operative equipment,
implants, antibiotics, anticoagulation, transfusions, postoperative recovery, length of hospital stay, readmission rates,
inpatient consults, inpatient physical therapy and investigations (including imaging and blood work) were obtained
using current administrative data from the case costing
department at our institution.
Statistical analysis
Microsoft Excel for Mac (version 15.31) was used for all
analyses. Descriptive statistics including means and ranges
were calculated to describe each cohort. Patients with PJI
were compared with the matched cohort of patients who
underwent primary THA using the χ2 test (for categorical
variables) and the t test (for continuous variables). The
Mann–Whitney test was applied where nonparametric data
were identified. The study was powered at 0.90 with an α
of 0.05 to detect a difference in overall cost between
cohorts. Statistical significance was considered at a p value
of less than 0.05.

Results
Sixty-one cases of infected THA were reviewed for entry
into this study; 11 of them were eventually excluded.
Seven patients were excluded because an initial irrigation
and débridement was performed at an outside institution
before the patient presented to our centre for staged
revision. Three patients were excluded because they died
before stage 2 revision could be completed, and 1 patient
was excluded after opting not to move forward with
stage 2. After exclusions, 50 cases of infected THA were
entered into our analysis and were compared with
50 cases of primary uncomplicated THA. The mean age
and BMI of patients was 64 (range 50–83) years and
32 (range 19–41) in the revision cohort and 67 (range
52–82) years and 29 (range 19–39) in the primary THA
cohort, respectively (Table 1).
Table 1. Patient characteristics
Cohort; mean (range)
Characteristic

Primary THA
n = 50

Infected THA
n = 50

p value

Age, yr

67 (52–82)

64 (50–83)

0.13

BMI

29 (19–39)

32 (19–41)

0.12

BMI = body mass index; THA = total hip arthroplasty.
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The average cost of 2-stage revision for infected THA
was Can$38 107 (range $17 789–$118 247). This proced
ure was 5.6 times more costly than the average primary
THA (Can$6764 [range $5823–$8523]) and the difference between groups was significant (p < 0.001) (Table 2).
The Mann–Whitney test was applied to correct for nonparametric data and also indicated statistical significance,
with the median cost of 2-stage revision being greater
than the median cost of primary THA (Can$29 711 v.
Can$6634, z = 7.03, p < 0.001). Six patients (12%) in the
cohort with infected THA required at least 1 repeat stage
1 revision before receiving a definitive second-stage surgery. Staphylococcus aureus was the most commonly isolated organism (38%) with the methicillin-resistant form
(MRSA) accounting for 22% of the infections in the
entire cohort of patients with infected THA. The average
cost associated with management of MRSA PJI was similar to the cost of managing other isolated pathogens
(Can$39 558 v. Can$40 065). PJI was also associated with
a significant increase in mean length of hospital stay (26.5
v. 2.0 d, p < 0.001), mean number of clinic visits (9.2 v.
3.8, p < 0.001) and number of readmissions
(12 v. 1, p < 0.001) when patients in the infected THA
group were compared with those who underwent primary
THA (Table 3). Inpatient resource use was also greater
among the patients with infected THA. There was an
8-fold increase in costs associated with laboratory testing
and imaging (Can$898 v. Can$116) and a 20-fold
increase in medications costs secondary to prolonged
antibiotic and anticoagulant use while in hospital
(Can$1167 v. Can$54) (Table 4).
Table 2. Average cost of total hip arthroplasty
Cohort; cost, Can$, mean (range)
Category

Primary THA

Infected THA

p value

Inpatient

1765
(924–3455)

21 387
(4825–77 009)

< 0.001

Operative

4998
(4039–5638)

16 720
(14 547–64 551)

< 0.001

Total

6764
(5823–8523)

38 107
(17 789–118 247)

< 0.001

THA = total hip arthroplasty.

Table 3. Length of hospital stay, clinic visits and readmissions
associated with primary and 2-stage revision total hip
arthroplasty
Cohort
Primary THA

Infected THA

p value

Mean length of hospital
stay, d

Outcome

2.0

26.5

< 0.001

Mean no. of clinic visits

3.8

9.2

< 0.001

1

12

< 0.001

No. of patients
readmitted
THA = total hip arthroplasty.
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Table 4. Summary of expenses in total hip arthroplasty
Cohort; cost, Can$, mean (range)
Resource

Primary THA

Infected THA

Operating room services

1701
(966–2194)

7392
(4976–21 265)

Implants

2452
(2427–2481)

6942
(4087–18 662)

Anesthesia

312
(210–402)

1530
(1062–4424)

Hospital bed charges

1394
(719–2624)

17 423
(3135–65 221)

Investigations

116
(20–387)

898
(391–2735)

Medications

54
(30–124)

1167
(142–3199)

Physical therapy

94
(47–141)

809
(157–3265)

THA = total hip arthroplasty.

Discussion
As annual THA volumes continue to increase, so too will
the number of revision procedures for management of
PJI. For every 9 patients who undergo primary THA, it
is estimated that 1 is admitted for revision.14 Periprosthetic joint infection is the third leading cause of failure
following primary THA,14 and treatment in the United
States alone was projected to impart a financial burden in
excess of US$400 million by 2020.6
In our study, 2-stage revision for PJI was associated with
a greater than 5-fold increase in hospital expenditure when
compared with primary uncomplicated THA. The bulk of
this expense (83%) was attributed to hospital bed charges,
operating room services and implant use. Patients who
underwent treatment for PJI were also more likely to be
readmitted, had more outpatient clinic visits and consumed
more resources than those who underwent primary THA.
To our knowledge, this is one of few studies to evaluate the
cost of PJI in THA using direct institutional case costing.10,11
This differs from most prior studies, which derived estimates from institutional billing data. This type of data may
vary greatly across institutions and its interpretation requires
knowledge of centre-specific cost-to-charge ratios.12 Direct
case costing, on the other hand, better reflects consumed
resources and services and thus more accurately reflects true
institutional burden. In theory, these data should be similar
among institutions that serve similar regions and operate
with similar practice patterns. Although the cost of delivering orthopedic care is substantially lower in Canada than in
other countries, the relative cost of primary and 2-stage revision is remarkably similar to that observed in the US. This
suggests that our data are generalizable and thus may be
used to guide future resource allocation and budget planning at tertiary centres that offer similar care.
Our study corroborates the findings of previously published work. Bozic and Ries10 conducted a retrospective cost

RESEARCH
analysis involving a cohort of 25 patients who underwent
2-stage revision for periprosthetic hip infection. In this
study the total hospital cost associated with treatment of
PJI was 4.4 times greater than the cost of primary THA
(US$96 166 v. US$21 654, p < 0.001). These authors also
noted a significant increase in length of hospital stay
(28.2 v. 6.2 d, p < 0.001) and outpatient visits among
patients treated with 2-stage revision (54.6 v. 17.2, p < 0.001).
Unlike us, these authors did not comment on other specific
factors that contributed to the cost of care in PJI.
Most recently, Kapadia and colleagues11 published the
results of a retrospective study examining the economic
impact of periprosthetic hip infection. In this study,
16 patients who underwent 2-stage revision were compared
with a cohort of patients who underwent primary uncomplicated THA. They analyzed a combination of billing and
direct cost data from their institution. Treatment of periprosthetic infection was found to be 3.5 times more costly
than primary THA (US$88 623 v. US$25 659, p < 0.001).
Similar to our study, Kapadia and colleagues 11 also
reported longer hospital stays (7.6 v. 3.3 d, p = 0.02), more
readmissions (2 v. 0, p < 0.0001) and a significant increase
in resource utilization among patients with periprosthetic
hip infection.11 Interestingly, average length of stay in the
infected cohort was much shorter than we observed in our
study (7.6 v. 26.5 d). This is an important finding given
that both studies identified length of hospital stay as the
greatest contributing factor to the total cost of care in
periprosthetic hip infection. Although this may indicate
a difference in practice pattern, it may also simply reflect a
difference in the way length of hospital stay was defined in
each study. In our study, length of hospital stay was calculated as the sum total of days spent in hospital across all
stages of revision. It should be noted that all patients were
discharged home between stages.
Collectively, this body of work suggests that the economic impact of PJI can be reliably estimated to be
4–5 times the cost of primary THA. In doing so, this study
also illustrates the need to further explore measures that may
contain or reduce the burden PJI. With length of hospital
stay contributing most significantly to the burden of care,
institutions may benefit from the creation of well-defined
clinical pathways, which better coordinate interdisciplinary
care. In our experience, similar pathways have shortened
hospital stays in primary arthroplasty and also enabled the
delivery of safe outpatient surgery in select patients.
Single-stage revision is a cost-effective approach that
continues to show promise in well-defined populations
with PJI of the hip, knee and shoulder.14,15,16 In 2012,
Beswick and colleagues14 performed a systematic review of
62 studies involving more than 4000 patients who were
treated with 1- or 2-stage revision for periprosthetic hip
infection. The incidence of recurrent infection was similar
between groups (10.2% [95% confidence interval (CI)
7.7%–12.9%] v. 8.6% [95% CI 4.5%–13.9%]). Although

weakened by heterogeneity, these findings suggests the
need for a prospective, randomized controlled trial to further evaluate the efficacy of single-stage revision for PJI.
Limitations
The limitations of this study are largely related to its retrospective design. Most notably, this study is susceptible to
selection bias. We aimed to minimize bias by entering
patients into the study in consecutive fashion and by limiting exclusion criteria. Cohorts were also matched for age
and BMI in an attempt to limit the influence of variables
that are known to effect resource utilization.17 The overall
accuracy of our estimate is closely tied to the quality of
available institutional data pertaining to resource utilization. Our system enabled us to identify most resources
using electronic medical records and intraoperative
reports; however, some expenses (for bowel regimens, antiemetics and analgesics, for example) are reliably captured
only prospectively. Although this is a limitation, it is
unlikely to have had a significant impact on the magnitude
of the difference between groups, given that these expenses
are quite small relative to more significant drivers of cost
such as LOS and operating room services. It should be
noted that this study does not capture out-of-pocket
patient expenses such as those related to prescription
medication, respite care and time away from employment
for both patients and their caregivers. Additionally, costs
pertaining to home-based physiotherapy, antibiotic administration, wound care and peripherally inserted central line
care were purposely not captured. We do not consider this a
limitation given that our aim was to strictly describe the
institutional cost burden of PJI in THA so that data can be
used as a resource for institutional budget planning. In
Canada, these outpatient expenses are directly funded by
the provincial and territorial governments.

Conclusion
Periprosthetic joint infection has a profound economic
impact on tertiary care centres. Our data suggest a 5-fold
increase in hospital expenditure in the management of PJI
when compared with primary uncomplicated THA. The
major cost-contributing factors are hospital bed, operating
room and implant expenses, which together accounted for
83% of total hospital expenditures in our study. These data
may be useful in guiding future resource allocation decisions
and institutional budget planning for THA. This study also
highlights the need for further investigation of potential costcontaining measures in the management of PJI.
Affiliations: From the Division of Orthopaedic Surgery, Department of
Surgery, Western University, London, Ont. (Akindolire, Morcos,
Marsh, Howard, Lanting, Vasarhelyi); and the Division of Orthopaedic
Surgery, London Health Sciences Centre, London, Ont. (Akindolire,
Morcos, Howard, Lanting, Vasarhelyi).
Can J Surg/J can chir 2020;63(1)

E55

RECHERCHE
Competing interests: J. Howard reports receiving grants from Stryker
and DePuy, personal fees from Stryker, DePuy, Smith & Nephew and
Intellijoint, and institutional research support from Stryker, DePuy,
Smith & Nephew, Zimmer and MicroPort, all outside the submitted
work. He holds stock in PersaFix Technologies. B. Lanting reports
receiving personal fees from Smith & Nephew, Stryker, DePuy, Integra
and Intellijoint, and institutional support from Smith & Nephew,
DePuy, Stryker and Zimmer, all outside the submitted work. E. Vasarhelyi
reports receiving grants from DePuy, grants and personal fees from
DePuy and Hip Innovation Technology, and institutional support
from DePuy, Stryker and Smith & Nephew, all outside the submitted
work. No other competing interests were declared.
Contributors: J. Akindolire, J. Howard, B. Lanting and E. Vasarhelyi
designed the study. All authors acquired and analyzed the data.
J. Akindolire, M. Morcos, J. Howard, B. Lanting and E. Vasarhelyi
wrote the article. All authors critically reviewed the article and approved
the final version for publication.

References
1. Agency for Healthcare Research and Quality. Healthcare Cost and
Utilization Project (HCUP), National Inpatient Sample (NIS).
Rockville (MD): Agency for Healthcare Research and Quality; 2014.
2. Hackett DJ, Rothenberg AC, Chen AF, et al. The economic significance of orthopaedic infections. J Am Acad Orthop Surg 2015;
23(Suppl):S1-7.
3. Kamath AF, Ong KL, Lau E, et al. Quantifying the burden of revision total joint arthroplasty for periprosthetic infection. J Arthroplasty
2015;30:1492-7.
4. Roth VR, Mitchell R, Vachon J, et al. Periprosthetic infection following primary hip and knee arthroplasty: the impact of limiting the
postoperative surveillance period. Infect Control Hosp Epidemiol
2017;38:147-53.
5. Bozic KJ, Katz P, Cisternas M, et al. Hospital resource utilization for
primary and revision total hip arthroplasty. J Bone Joint Surg Am
2005;87:570-6.

E56

Can J Surg/J can chir 2020;63(1)

6. Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty
2012;27(Suppl):61-5.e1.
7. Senthi S, Munro JT, Pitto RP. Infection in total hip replacement:
meta-analysis. Int Orthop 2011;35:253-60.
8. Parvizi J, Zmistowski B, Adeli B. Periprosthetic joint infection: treatment options. Orthopedics 2010;33:659.
9. Barnes CL, Vail TP, Takemoto SK. Where do knee revisions for
infection, fracture, and other revisions get treated? J Arthroplasty
2013;28:423-8.
10. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg
2005;87:1746-51.
11. Kapadia BH, Banerjee S, Cherian JJ, et al. The economic impact of
periprosthetic infections after total hip arthroplasty at a specialized
tertiary-care center. J Arthroplasty 2016;31:1422-6.
12. Bozic KJ, Kamath AF, Ong K, et al. Comparative epidemiology of
revision arthroplasty: failed THA poses greater clinical and economic
burdens than failed TKA. Clin Orthop Relat Res 2015;473:2131.
13. Parvizi J, Gehrke T, International Consensus Group on Periprosthetic Joint Infection. Definition of periprosthetic joint infection.
J Arthroplasty 2014;29:1331.
14. Beswick A, Elvers K, Smith A, et al. What is the evidence base to
guide surgical treatment of infected hip prostheses? Systematic
review of longitudinal studies in unselected patients. BMC Med
2012;10:18.
15 Zeller V, Lhotellier L, Marmor S, et al. One-stage exchange arthroplasty for chronic periprosthetic hip infection: results of a large prospective cohort study. J Bone Joint Surg Am 2014;96:e1.
16. Stone GP, Clark RE, O’Brien KC, et al. Surgical management of
periprosthetic shoulder infections, J Shoulder Elbow Surg 2017;26:
1222-1229.
17. Huddleston JI, Wang Y, Uquillas C, et al. Age and obesity are risk
factors for adverse events after total hip arthroplasty. Clin Orthop
Relat Res 2012;470:490-6.

